• Research
    • Research groups
    • Functional Genomics Area
    • Strategic Line 1: The Human Genome
    • Strategic Line 2: Cancer Genomics
    • Personalised Medicine Area
    • Strategic Line 3: Detection, Diagnostics, Monitoring and Prognostics of Diseases
    • Strategic Line 4: Advanced Therapies
    • Publications
    • International Projects

There are no projects in the garbage can.

  • WebMail
  • Private area
  • Español
  • Center
    • What is GENyO?
    • Support Units
    • Management Units
    • Strategic Plan 2024-2027
    • Transparency
    • Contact
  • Events and news
    • News
    • Events
    • Scientific Conferences
    • Galleries
  • GENyO TV
  • Research
    • Research groups
    • Functional Genomics Area
    • Strategic Line 1: The Human Genome
    • Strategic Line 2: Cancer Genomics
    • Personalised Medicine Area
    • Strategic Line 3: Detection, Diagnostics, Monitoring and Prognostics of Diseases
    • Strategic Line 4: Advanced Therapies
    • Publications
    • International Projects
  • Center
    • What is GENyO?
    • Support Units
    • Management Units
    • Strategic Plan 2024-2027
    • Transparency
    • Contact
  • Events and news
    • News
    • Events
    • Scientific Conferences
    • Galleries
  • GENyO TV
  • WebMail
  • Private area
  • Español

There are no projects in the garbage can.

International Projects

Optimize and scale up the production of iTRUCK1918 cells

Home

Optimize and scale up the production of iTRUCK1918 cells

Optimize and scale up the production of iTRUCK1918 cells

Optimize and scale up the production of universal anti-CD19 CAR-T cells (UCARARI)

Optimize and scale up the production of universal anti-CD19 CAR-T cells (UCARARI)

Predicting Response and Non-Response to Therapy in SLE

Predicting Response and Non-Response to Therapy in SLE

SIGNATURE – Single cells in autoimmune inflammatory diseases

SIGNATURE – Single cells in autoimmune inflammatory diseases

GenE-Humdi – Genome Editing for the treatment of human Disease Network

GenE-Humdi – Genome Editing for the treatment of human Disease Network

Program SPARK THERAPUTICS INC

Program SPARK THERAPUTICS INC

3TR – TAXONOMY, TREATMENT, TARGETS & REMISSION

3TR – TAXONOMY, TREATMENT, TARGETS & REMISSION

Research

Publications

See more

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.

Authors: Álvarez-Pérez JC, Sanjuán-Hidalgo J, Arenas AM, Hernández-Navas I, Benitez-Cantos MS, Andrades A, Calabuig-Fariñas S, Jantus-Lewintre E, Paz-Ares L, Ferrer I, Medina PP

09/2025 - Nature communications

The effects of a supervised exercise training program during pregnancy on placental cytokines, and the potential role of fetal sex and maternal weight status.

Authors: Acosta-Manzano P, Flor-Alemany M, Martínez-González LJ, Alvarez-Cubero MJ, Baena-García L, Nestares T, Van Poppel MN, Aparicio VA

08/2025 - Journal of sport and health science

Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case.

Authors: Puig-Serra P, Hinckley-Boned A, Tristán-Manzano M, Rio P, Torres-Ruiz R, Rodriguez-Perales S, Martín F

09/2025 - Human gene therapy

    Transparency

  • Documents of interest
  • Organizational structure
  • Organizational chart

    Research

  • Research groups
  • Functional Genomics Area
  • Personalised Medicine Area
  • International Projects
  • Publications

    Center

  • What is GENyO?
  • Support Units
  • Management Units
  • Strategic Plan 2024-2027
  • Transparency
  • Contact

    Events and news

  • News
  • Events
  • Scientific Conferences
  • Galleries

Address

Avda. de la Ilustración 114.
18016 Granada, Spain

+34 958 715 500
info@genyo.es
  • Company affiliation

    2025 @Genyo All rights reserved

  • Legal note
  • Cookies Policy
  • Privacy Policy